CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Pentoxifylline +1 moredrug
Likely dose
Pentoxifylline 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00796822
NCT00796822Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy

Indiana University·interventional·Posted Nov 24, 2008·Updated Nov 28, 2017

In Brief

A Phase 2 clinical trial evaluating Pentoxifylline and Placebo for HIV and 2 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation brought on by either the HIV infection itself or the use of antiretroviral medications to treat HIV infection. This study will evaluate an anti-inflammatory drug, pentoxifylline, to determine whether it improves blood vessel function and reduces inflammation in people infected with HIV who are not currently receiving antiretroviral medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Cardiovascular Diseases, Atherosclerosis
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 24, 2008
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.6 years ago

Interventions

Pentoxifyllinedrug

400 mg three times a day for 8 weeks

Placebodrug

One pill three times a day for 8 weeks